REPL - NASDAQ
Replimune Group, Inc.
$10.54
+19%Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
At a Glance
Live SnapshotReplimune Group, Inc. Management Team
Mr. Andrew Schwendenman
Chief Accounting Officer & Treasurer
Mr. Christopher Sarchi
Chief Commercial Officer
Dr. Sushil Patel Ph.D.
Chief Executive Officer & Director
Compensation
$665,050
Ms. Emily Luisa Hill
Chief Financial Officer
Compensation
$593,047
Mr. Camilo Garcia M.A., M.B.A.
Chief Human Resource Officer
Mr. Paul Bullock
Chief Manufacturing Officer & Framingham Site Head
Dr. Konstantinos Xynos M.B.A., M.D., Ph.D.
Chief Medical Officer
Compensation
$668,686
Mr. Philip Astley-Sparke F.S.A.
Executive Chairman
Compensation
$960,520
Mr. Shawn Glidden J.D.
Senior Vice President of General Counsel
Ms. Nina Aragam
Senior Vice President of Portfolio Strategy & Program Management
Replimune Group, Inc. Insider Positioning
During the last 12 months, insiders have sold $944K worth of REPL shares, with no buying activity reported.
3 Months
0
0.00
111.8K
637.09K
-637K
-$637K
3-6 Months
0
0.00
3.2K
32.96K
-33K
-$33K
6-9 Months
0
0.00
22.5K
224.65K
-225K
-$225K
9-12 Months
0
0.00
9.2K
49.16K
-49K
-$49K
Top Buyers
No buying activity
Top Sellers
Patel Sushil
Director, Officer: Chief Executive Officer
$301K
Sarchi Christopher
Officer: Chief Commercial Officer
$254K
Xynos Konstantinos
Officer: Chief Medical Officer
$137K
Astley-Sparke Philip
Director
$90K
Hill Emily Luisa
Officer: Chief Financial Officer
$89K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $944K net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
5 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
Insider Activity Insight
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
SEC Filings
REPL - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2025 N/A | July 25, 2025 | September 03, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | July 19, 2024 | September 04, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | July 26, 2023 | September 06, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | July 27, 2022 | September 07, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | July 22, 2021 | September 08, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | July 29, 2020 | September 09, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | August 09, 2019 | September 04, 2019 | 2019 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.